<DOC>
	<DOCNO>NCT02502097</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , crossover , dose escalation study AF-219 subject Idiopathic Pulmonary Fibrosis ( IPF ) persistent cough .</brief_summary>
	<brief_title>A Study AF-219 Subjects With Idiopathic Pulmonary Fibrosis ( IPF ) With Persistent Cough</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Idiopathic pulmonary fibrosis diagnosis base upon American Thoracic Society ( ATS ) / European Respiratory Society ( ERS ) /Japanese Respiratory Society ( JRS ) / Latin American Thoracic Society ( ALAT ) IPF 2011 guideline Life expectancy great 6 month Stable medical condition ( IPF ) least 4 week Selfreported history troublesome daily cough 8 week Score ≥ 40mm Cough Severity VAS Screening Women childbearing potential must use 2 form acceptable birth control method Screening FollowUp Visit Male subject partner childbearing potential must use 2 method acceptable birth control Screening 3 month last dose study drug Written inform consent Willing able comply aspect protocol Current smoker ( i.e. , within last 30 day ) . Initiation treatment ACEinhibitor within 4 week prior Baseline Visit ( Day 0 ) study History upper respiratory tract infection within 4 week Baseline Visit ( Day 0 ) History opioid use treatment cough within 1 week Baseline Visit ( Day 0 ) Requiring prohibit medication Body mass index ( BMI ) &lt; 18 kg/m2 ≥ 40 kg/m2 History concurrent malignancy recurrence malignancy within 2 year prior Screening ( include subject &lt; 3 excise basal cell carcinoma ) History diagnosis drug alcohol dependency abuse within approximately last 3 year Any condition possibly affect drug absorption ( e.g. , gastrectomy , gastroplasty , type bariatric surgery , vagotomy , bowel resection ) Recent history stroke transient ischemic attack ( within 6 month prior Screening ) due trauma , repair vascular malformation , aneurysm Screening systolic blood pressure ( SBP ) &gt; 160 mm Hg diastolic blood pressure ( DBP ) &gt; 90 mm Hg QTc interval &gt; 450 millisecond male , &gt; 470 millisecond female Significantly abnormal laboratory test Screening Breastfeeding Treatment investigational drug biologic within 30 day precede first dose study medication plan take another investigational drug biologic within 30 day study completion Blood donation within 56 day plasma donation within 7 day prior dose Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>